Tscan therapeutics reports first quarter 2025 financial results and provides corporate update

Updates from the plexi-t™ solid tumor and alloha™ heme phase 1 clinical trials anticipated by end of year on-track to file ind application for tsc-102-a0301 (cd45; hla-a*03:01) to fda in the second half of the year appointed commercial leader stephen camiolo as senior vice president, market access cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 waltham, mass., may 06, 2025 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biotechnology company focused on the development of t cell receptor (tcr)-engineered t cell (tcr-t) therapies for the treatment of patients with cancer, today reported financial results for the three months ended march 31, 2025, and provided a corporate update.
TCRX Ratings Summary
TCRX Quant Ranking